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Introduction: Wide local excision and adjuvant radiotherapy is the standard of care for early breast can-
cer. For large tumours, however, mastectomy is frequently recommended as conventional breast-
conserving techniques often result in poor cosmetic outcomes. Therapeutic mammaplasty (TM) may
extend the boundaries of breast-conserving surgery by combining breast reduction and mastopexy tech-
niques with tumour excision, preserving a natural breast shape and avoiding the need for mastectomy.
The prevalence of this operative option among surgeons in the UK and its success rate are unknown.
The TeaM study is a multicentre prospective study that aims to investigate the practice and outcomes
of TM.
Methods and analysis: Breast centres performing TM will be invited to participate through the research
collaborative network and the professional associations. All patients undergoing TM between
September 2016 and March 2017 will be included. Demographic, operative, oncological and complication
data within 30-days of surgery will be collected. The primary outcome will be unplanned re-operation for
complications. Secondary outcomes will include unplanned readmission, re-excision rates and time to
adjuvant therapy. Prospective data on 500 patients from 50 centres are anticipated. Exploratory analyses
will identify predictors for complications and inform the design of a definitive study.
4 E. Baker et al. / International Journal of Surgery Protocols 1 (2016) 3–10Ethics and dissemination: Research ethics approval is not required for this study. This has been confirmed
by the on-line Health Research Authority decision tool. This study will provide novel information regard-
ing the practice and outcomes of TM in the UK. This will inform decision-making for patients and sur-
geons and inform future research. Dissemination of the study protocol will be via the Mammary Fold
Academic and Research Collaborative, the Reconstructive Surgery Trials Network and the professional
associations, the Association of Breast Surgery and British Association of Plastic, Reconstructive and
Aesthetic Surgeons. Results will be presented at relevant surgical conferences and published in peer-
reviewed journals.
 2016 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Wide local excision (WLE) and adjuvant radiotherapy is the
standard of care early breast cancer [1,2]. For large tumours, how-
ever, mastectomy is frequently recommended as conventional
techniques often result in unacceptable cosmetic outcomes [3]
which can adversely affect patient satisfaction and quality of life
[4]. Therapeutic mammaplasty (TM) is a new technique that may
extend the boundaries of breast-conserving surgery by combining
breast reduction and mastopexy techniques with tumour excision
[5,6]. These techniques facilitate adequate resection of larger
tumours while preserving a natural breast shape in women with
medium to large breasts [7–10]; provide an alternative to mastec-
tomy with or without reconstruction in those with ptotic breasts
[6] and may improve outcomes for women with large breasts in
whom standard wide local excision followed by radiotherapy
may be associated with lymphoedema, fibrosis and chronic pain
[11].
Despite the widespread adoption of TM into practice, there is
limited high-quality evidence to support the benefits of this
approach. The majority of published studies are small, single cen-
tre, often retrospective case-series with inconsistent and heteroge-
neous outcome reporting, the results of which cannot be relied
upon. Three recent systematic reviews [11–13] have highlighted
the paucity of high-quality outcome data and emphasised the
urgent need for well-designed prospective studies to establish
the current indications and outcomes of TM. Particular uncertain-
ties relate to the practice of TM in patients with large tumours
(>4 cm) beyond the scope of traditional breast conservation; rates
and management of margin positivity; predictors of adverse out-
comes; the impact of TM on delivery of adjuvant therapy and
appropriate assessment of key patient-reported outcomes includ-
ing quality of life. Data to address these issues and the impact of
TM on long-term oncological outcomes such as local recurrence
are needed if the procedure is to be offered and bench-marked
appropriately. There are, however insufficient data regarding the
current indications and outcomes of TM in the UK to allow a defini-
tive study to be designed.
A large prospective study of the current practice of TM is there-
fore needed to inform the design of a definitive study. Such studies
are challenging, but the trainee research collaborative model [14]
has emerged as a time and cost-effective means of conducting
high-quality large-scale research [15] and audit [16] in surgery.
Recent successes with iBRA (implant Breast Reconstruction evAlu-
ation Study)
[17–19] and MasDA (Mastectomy Decisions Audit) and the
development of a national breast surgical research collaborative
[20] have demonstrated that the methodology is both feasible
and effective within the context of breast surgery. It is anticipated
that this network of highly-motivated breast and plastic surgical
trainees and consultants can be utilised to deliver a new study to
determine the practice and outcomes of therapeutic mammaplasty
in the UK.2. Methods and analysis
2.1. Aims and objectives
The primary aim of the TeaM (Therapeutic Mammaplasty)
Study is to evaluate the current practice and outcomes of therapeu-
tic mammaplasty in the UK.
This will be achieved using the following specific objectives:
i. To determine the number of breast and plastic surgical units
offering TM across the UK and the volumes of procedures
performed.
ii. To describe the current practice of TM including the indica-
tions and techniques used.
iii. To evaluate the 30 day clinical outcomes of TM and explore
predictors for adverse outcomes.
iv. To determine the impact of TM on the time to delivery of
adjuvant therapy.
v. To establish a network of units performing TM for future
research studies.
vi. To inform the feasibility, design and conduct of a future
definitive large-scale study including patient-reported and
long-term oncological outcomes of TM procedures.
2.2. Hypothesis
Therapeutic mammaplasty is a safe and effective technique for
women undergoing breast conserving surgery for invasive or pre-
invasive breast cancer with rates of unplanned return to theatre
and unplanned readmission to hospital for complications within
nationally-defined guidelines for oncoplastic surgical procedures
[21].2.3. Study design
This study will be undertaken employing a national multi-
centre prospective cohort design using the research collaborative
model previously-reported [14] coordinated by the TeaM Study
Steering Group.2.3. Setting
All breast or plastic surgical units in the UK performing TM will
be eligible to participate in the study. Units will be invited to par-
ticipate via the collaborative groups (Mammary Fold Academic and
Research Collaborative (MFAC), the Reconstructive Surgery Trials
Network (RSTN) and the National research collaborative network)
and the professional associations (Association of Breast Surgery
(ABS), British Association of Plastic Reconstructive and Aesthetic
Surgeons (BAPRAS) and the Association of Surgeons in Training
(ASiT)).
Table 1
Secondary outcome measures.
Outcome measure Definition
Unplanned re-operation for
local complications
Any re-operation in the 30 days of the initial
operation for complications of the TM
procedure
Any planned return to theatre for oncological
reasons such as axillary clearance or further
excision of margins as decided at the
multidisciplinary team (MDT) meeting or
following review of surgical pathology will NOT
be included in this category
Re-admission to hospital Any re-admission to hospital following
discharge home after TM directly related to the
procedure with either local or systemic
complications within 30 days of surgery
Re-excision of
margins/completion
mastectomy
Any return to theatre for removal of additional
tissue in a second operation due to one or more
involved/positive margins as recommended by
the local multi-disciplinary team. This will
include re-excision of margins or completion
mastectomy as determined by local MDT
decision or elected by patient choice
Involved margins will be defined as invasive
tumour or ductal carcinoma in situ at or close
to the resection margin requiring further
surgery (re-excision of margins or completion
mastectomy) as defined by local MDT policy
(e.g. tumour at ink/<1 mm/<2 mm)
Completion mastectomy will be defined as the
complete removal of the remaining breast
tissue as elected by MDT decision or patient
choice.
Time to delivery of
adjuvant therapy
Time in days from the TM (or LAST oncological
surgery, if applicable) to the first adjuvant
treatment (1st dose of chemotherapy or first
fraction of radiotherapy)
MDT; multidisciplinary team; TM – Therapeutic mammoplasty.
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2.4.1. Inclusion criteria
All female patients over the age of 18 undergoing a therapeutic
mammaplasty (TM) procedure. For the purpose of this study, TM
will be defined as ‘the oncoplastic application of breast reduction
or mastopexy techniques including removal of skin to reduce the
skin envelope to treat invasive or pre-invasive (ductal carcinoma
in situ; DCIS) breast cancer using breast conserving surgery
(BCS)’ [5,6]. The nipple may or may not be removed pending onco-
logical indication. This will include the following techniques:
 Wise pattern reduction patterns
 Vertical scar mammaplasty techniques
 Benelli mammaplasty techniques
 Tennis racket mammaplasty
 Grisotti flaps
 Horizontal wedge excision
2.4.2. Exclusion criteria
Patient undergoing:
 Standard wide local excision not using any of the techniques
listed above
 BCS combined with volume replacement procedures such as
latissimus dorsi (LD) mini-flaps, thoracodorsal artery perforator
(TDAP) or lateral intercostal artery perforator (LICAP) flaps
 Breast reduction or mastopexy to achieve symmetry or improve
the appearance of the breast in a separate procedure from the
initial tumour resection
 Mastectomy with or without immediate reconstruction
 Surgery for indications other than invasive or pre-invasive
disease
2.5. Outcome measures
The primary outcome will be unplanned re-operation for com-
plications within 30 days of the TM procedure. This is based on
the ABS and BAPRAS Oncoplastic Surgery: Guidelines for Best Prac-
tice [21] quality criteria (QC16) which states that less than 5% of
patients should return to theatre for local complication including
wound infection, wound problems requiring debridement or hae-
matoma requiring evacuation [21]. Secondary outcomes will
include unplanned re-admission to hospital following discharge
home; re-excision of margins, and time to delivery of adjuvant
therapy (Table 1). The National Institute for Health and Care Excel-
lence recommends that adjuvant therapy is delivered ‘‘as soon as
clinically possible within 31 days of completion of surgery” [22].
2.6. Data collection
It is expected that participating centres will recruit consecutive
patients into the study. The completeness of case ascertainment
will be determined by independent validation of procedure num-
bers and data collection in selected sites. Any disparity will be
explored with the unit concerned and any unit determined to have
recruited patients selectively will be excluded from the analysis
(see QA section).
All women undergoing TM as previously defined will be identi-
fied prospectively from clinics, multidisciplinary team (MDT)
meetings and theatre lists.
Simple demographic, co-morbidity, pre-operative planning,
operative and oncology data will be collected for all patients. Deci-
sions regarding adjuvant treatment recommendations will be iden-
tified from the post-operative MDT meeting.Data regarding 30 day complications, re-admission and re-
operation will be collected prospectively by clinical or case-note
review in those not attending for follow-up. Date of commence-
ment of adjuvant therapy will be identified by a review of relevant
hospital systems. The required data fields are shown in Table 2 and
definitions and categorisation of complications summarised in
Table 3.
Data will be recorded in an anonymised format using a unique
alphanumeric study identification number on a secure web-based
database (REDCap) designed by Vanderbilt University [23] (http://
www.projectredcap.org/). Advanced branching logic will be used
such that only data fields relevant to the type of surgery will be
displayed in later data collection forms. It is anticipated this will
reduce the burden of participation for collaborators and optimise
the quality of data collected during the study. The data forms
and database will be extensively trialled in a three centre pilot
prior to national roll-out of the study. This will validate the logic
used and ensure that the forms are complete, user friendly, and
allow for any errors to be corrected prior to main study initiation.2.7. Data validation and management
Following data collection, only data sets with >75% data com-
pleteness will be included in the analysis [24]. For quality assur-
ance purposes, the consultant principal investigator at selected
sites will be asked to identify an independent person to validate
a proportion of the submitted data. Overall, approximately 5% of
the datasets will be independently validated. The independent
assessors will also be asked to examine theatre logbooks, operating
diaries and Trust computer systems to check case ascertainment. If
concordance between the number of cases submitted on REDcap
Table 2
Data fields for the TeaM study.
Field Options (definitions)
Section 1 – Demographic data
Age Age at diagnosis in years
Height In metres
Weight In kilograms
Body mass index Actual BMI will be collected and categorised as
Underweight (<18.5 kg/m2)
Normal weight (18.5–24.9 kg/m2)
Overweight (25–29.9 kg/m2)
Obese (30–34.9 kg/m2)
Severely obese (35–39.9 kg/m2)
Morbid obesity (>40 kg/m2)
Bra Size Back and cup size
Sternal notch to nipple distance In centimetres
Smoking status Current smoker/Ex-smoker >6 weeks/Non-smoker/Nicotine replacement
Diabetic Yes/No
Other co-morbidities Ischaemic heart disease (yes/no); Current steroid therapy (yes/no); Other immunosuppressive therapy
(yes/no); Connective tissue disease (yes/no); Other co-morbidity (yes/no) with details
Section 2 – Prior and neoadjuvant treatments
Previous radiotherapy to ipsilateral breast Yes/No
Neoadjuvant chemotherapy Yes/No
Neoadjuvant radiotherapy Yes/No
Neoadjuvant endocrine therapy Yes/No
Previous surgery to ipsilateral breast Wide local excision (yes/no, if yes, date MM/YY);
Breast reduction (yes/no, if yes, date MM/YY);
Breast augmentation (yes/no, if yes, date MM/YY);
Other (yes/no, if yes, date MM/YY)
Section 3 – Pre-operative planning data
Initial presentation Screening/Symptomatic
Breast affected Right/Left/Bilateral
For each affected breast
Predominant location of tumour by quadrant Upper outer/Upper inner/Lower inner/Lower outer/Central
Type of lesion Ductal carcinoma in situ only/Invasive ductal cancer/Invasive lobular cancer/Other
Grade Cancer: 1/2/3
DCIS: Low/Intermediate/High
Maximum size of lesion at diagnosis on pre-operative imaging
in 2 dimensions
Size in largest diameter (mm)
Maximum size of lesion on pre-operative imaging AFTER neo-
adjuvant therapy (if used) in 2 dimensions
Size in largest diameter (mm)
Focality Unifocal (one lesion)/Multifocal (two distinct separate lesions)
Contralateral symmetrisation Planned simultaneous to TM/Planned for later date/Patient declined
Other treatment options offered to the patient (please tick all
that apply)
Standard wide local excision
Mastectomy alone
Mastectomy with immediate implant-based breast reconstruction
Mastectomy with immediate autologous breast reconstruction
Indications for therapeutic mammaplasty (please tick all that
apply)
To avoid mastectomy
To avoid poor cosmetic outcome associated with standard wide local excision
To avoid problems associated with radiotherapy in patients with large breasts
Large tumour
Quality of life benefits
Other
Section 4 – Operative data
Date of therapeutic mammaplasty Day/month/year
ASA grade 1 – Normal healthy individual
2 – Mild systemic disease that does not limit activities
3 – Severe systemic disease that limits activities but is not
incapacitating
4 – Incapacitating systemic disease which is constantly life threatening
Name of consultant surgeon
Duration of procedure Knife to skin to dressings on in minutes
Procedure details collected for RIGHT and LEFT breasts separately. Therapeutic mammaplasty dataset
Procedure performed None
Therapeutic mammaplasty
Reduction/mastopexy for symmetrisation
Mastectomy alone
Mastectomy and implant-based breast reconstruction
Mastectomy and autologous breast reconstruction
Other (free text)
The following data will be collected for each TM procedure performed
Grade of primary operating surgeon Consultant/Associate Specialist/Senior trainee (ST8+ or Oncoplastic Fellow/ST6-7/ST5 or below/Other
Number of TMs performed using this method in total <5/5–10/10–25/>25
Number of TMs performed using this method unsupervised <5/5–10/10–25/>25
Pre-operative localisation Yes/No
If yes – bracketed Yes/No
Nipple preserved Yes on a pedicle/Yes as a free nipple graft/No
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Table 2 (continued)
Field Options (definitions)
Skin incision used Peri or circumareolar with skin excision (round block/Benelli/Racquet)
Wise-pattern/Inverted T
Single vertical scar/LeJour
Grisotti – for central cancers removing nipple
Melon slice or horizontal wedge excision (±nipple)
Other
Pedicle(s) used to preserve the nipple (if nipple preserved) Superior/Supero-medial/Medial/Inferior/Central mound/Dual pedicle/Other with details
Tumour excision Wide local excision performed first followed by the reduction/mastopexy
Wide local specimen incorporated in reduction specimen; both procedures performed simultaneously
Intraoperative confirmation of excision None/Specimen X-ray/Intra-operative frozen section/Intra-operative margin technology e.g. iKnife/
Other
Volume of wide local excision In grams
Total volume of breast tissue excised (wide local excision + all
excised breast tissue)
In grams
Method of marking tumour bed None/Single clip/Clips to all margins
Axillary surgery None/Sentinel node biopsy/axillary sample/Axillary clearance
Drains used Yes/No
Reduction/mastopexy dataset (for patients undergoing simultaneous contralateral symmetrisation)
Grade of primary operating surgeon Consultant/Associate Specialist/Senior trainee (ST8 + or Oncoplastic Fellow/ST6-7/ST5 or below/Other
Number of reductions/mastopexies performed using this
method in total
<5/5–10/10–25/>25
Number of reductions/mastopexies performed using this
method unsupervised
<5/5–10/10–25/>25
Skin incision used Peri or circumareolar with skin excision (round block/Benelli/Racquet)
Wise-pattern/Inverted T
Single vertical scar/LeJour
Grisotti – for central cancers removing nipple
Melon slice or horizontal wedge excision (±nipple)
Other
Pedicle(s) used to preserve the nipple (if nipple preserved) Superior/Supero-medial/Medial/Inferior/Central mound/Dual pedicle/Other with details
Total volume of breast tissue excised In grams
Drains used Yes/No
Section 5 – Post-operative oncology and MDT outcomes
Pathology details for RIGHT and LEFT breasts will be collected separately
Type of lesion Ductal carcinoma in situ only/Invasive ductal cancer/Invasive lobular cancer/Other
Grade of invasive disease/DCIS 1 – Low grade (DCIS) or well-differentiated (invasive)
2 – Intermediate grade (DCIS) or moderately differentiated (invasive)
3 – High grade (DCIS) or poorly differentiated (invasive)
Focality Unifocal – one lesion/Multifocal – two distinct separate lesions
Size of invasive tumour mm (largest if > 1 ipsilateral tumour)
Total size of lesion including DCIS In pathological specimen (mm)
Fully excised by local criteria? Yes/No
Lymph node involvement Number of involved lymph nodes (macro-metastases only)
ER status Positive/Negative/Not known
HER2 status Positive/Negative/Not known
If not fully excised
MDT decision Re-excision of margins/Mastectomy/Chemotherapy followed by re-excision of margins/
Chemotherapy followed by mastectomy ± reconstruction
Re-excision 1
Date of surgery Day/Month/Year
Surgery performed Re-excision of margins/Completion mastectomy
Specimen weight In grams
Cancer/DCIS in re-excision specimen Yes/No
If yes, details
Margins clear Yes/No
If margins not clear, MDT decision Re-excision of margins/Mastectomy/Chemotherapy followed by re-excision of margins/
Chemotherapy followed by mastectomy ± reconstruction
Re-excision 2
Date of surgery Day/Month/Year
Surgery performed Re-excision of margins/Completion mastectomy
Specimen weight In grams
Cancer/DCIS in re-excision specimen Yes/No
If yes, details
Margins clear Yes/No
If margins not clear, MDT decision Re-excision of margins/Mastectomy/Chemotherapy followed by re-excision of margins/
Chemotherapy followed by mastectomy ± reconstruction
Re-excision 3
Date of surgery Day/Month/Year
Surgery performed Re-excision of margins/Completion mastectomy
Specimen weight In grams
Cancer/DCIS in re-excision specimen Yes/No
If yes, details
Margins clear Yes/No
(continued on next page)
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Table 2 (continued)
Field Options (definitions)
Oncological decisions
This section documents the time from LAST CANCER SURGERY to FIRST ADJUVANT TREATMENT i.e. first dose of chemotherapy or first fraction of radiotherapy. If patient
scheduled for chemotherapy and radiotherapy, please just record the date of first dose of chemotherapy
Date of last cancer surgery DD/MM/YY
Total size of lesion (mm) (if re-excisions)
Chemotherapy recommended by MDT Yes/No/already given
If yes
Date of recommendation Date/Month/Year
Patient accepts chemotherapy Yes/No
Chemotherapy start date Date/Month/Year
Radiotherapy recommended by MDT Yes/No/already given
If yes
Date of recommendation Date/Month/Year
Boost to tumour bed Yes/No
Radiotherapy start date Date/Month/Year
Section 6 – 30 day complication data
Please record any complications that occurs within in the first 30 days following surgery
Post-operative complication experienced Yes/No
If yes – details of surgical complications experienced (see
Table 3 for definitions)
Seroma
Haematoma
Infection
Skin flap necrosis
Nipple necrosis
Wound dehiscence
In hospital complications including systemic complications Yes/No
If yes, details
Re-admission to hospital Yes/No
If yes – date of readmission (day/month/year)
Reason for re-admission
Return to theatre Yes/No
If yes – date of re-operation (day/month/year)
Reason for return to theatre
Initial length of stay Day-case/23 h stay/in patient
ASA – American society of Anesthesiology; DCIS – ductal carcinoma in situ; MDT – multidisciplinary team; TM – therapeutic mammaplasty.
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excluded from the analysis. This is consistent with the quality
assurance procedure used in other large collaborative audit
projects [24].
Data collection will occur in accordance with Caldicott II princi-
ples (http://systems.hscic.gov.uk/infogov/caldicott/caldresources).
Data for each patient will be anonymised using a unique alphanu-
meric study identification number. No patient identifiable data will
be recorded centrally for the purpose of the audit.
Study data will be collected and managed using REDCap elec-
tronic data capture tools hosted at University of Oxford [23]. RED-
Cap (Research Electronic Data Capture) is a secure, web-based
application designed to support data capture for research studies,
providing (1) an intuitive interface for validated data entry; (2)
audit trails for tracking data manipulation and export procedures;
(3) automated export procedures for seamless data downloads to
common statistical packages; and (4) procedures for importing
data from external sources.
2.8. Anticipated recruitment
Data regarding the numbers of TM procedures performed
nationally are lacking. A national survey of specialist centres, how-
ever, suggests that between 10 and 20 TM procedures per centre
per year may be a reasonable estimate of volume per centre [25].
It is anticipated that the majority of the 144 breast units in the
UK will offer TM to their patients. Based on experience from the
iBRA study [26] and other trainee collaborative projects [20],
approximately 40% of units will choose to participate in the study.
It is therefore anticipated that between 250 and 500 patients will
be recruited to the study from approximately 50 centres over a
six month period. No formal power calculation has been per-formed, but it is anticipated that data from this study will be used
to inform the sample size for the definitive study.2.9. Study timelines
Data collection and analysis will be undertaken using the fol-
lowing time line
 June-August 2016 – Three centre pilot study, refining of data
collection forms
 June-August 2016 – Registration of interest from breast and
plastic surgical units. Local unit audit approvals obtained. Par-
ticipating centres will be required to have registered the study
and obtained local approvals prior to the main study start date
of 1st September 2016
 1st September 2016–28th February 2017 – Main study patient
recruitment; patients undergoing therapeutic mammaplasty
with operation dates between 1st September 2016 and 29th
February 2017 are eligible for inclusion in the study
 28th April 2017 – deadline for data submission
 1st July 2017 – Data validation complete
 30th August 2017 – Initial data analysis completed
2.10. Statistical analysis
The study report will be prepared according to the STROBE
(Strengthening the Reporting of Observational Studies in Epidemi-
ology) reporting guidelines for observational studies [27]. All data
analysis will occur centrally by the TeaM study team with support
from statisticians and methodologists in the RCS Surgical Trials
Centre.
Table 3
Definitions of 30 day complications.
Complication Definition Classification
Seroma A symptomatic collection of fluid in the operated breast Only seroma requiring aspiration to be recorded
Haematoma A collection of blood in the operated breast Minor – managed conservatively
Major – requiring surgical evacuation
Infection A hot, red swollen breast associated with one of the following; a
temperature, pus at the wound site, a raised white cell count; a
positive wound culture within the first 30 days of surgery.
Minor – requiring oral antibiotics
Major 1 – requiring admission for IV antibiotics
Major 2 – requiring surgical drainage or debridement (under GA)
Skin necrosis Any area of skin loss on the operated breast including the T junction Minor – managed conservatively with dressings
Major – requiring surgical debridement (under GA)
Nipple necrosis Any area of necrosis of the nipple areolar complex Minor – managed conservatively with dressings
Major 1 – requiring surgical debridement
Major 2 – complete nipple loss
Wound dehiscence Separation of the skin edges at the wound site Minor – managed conservatively
Minor – requiring return to theatre for re-suturing
GA – general anaesthetic.
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and multivariate regression analysis used to control for predictive
variables. Data will be tested for distribution and differences
between clinically relevant groups using unpaired t-tests, Mann-
Whitney U tests and Chi squared tests as appropriate. Exploratory
analyses will be performed to explore predictors for complications
and generate hypotheses for future studies. Summary statistics
will be calculated for each participating Trust and fed back to indi-
vidual units to allow comparison with national averages and
ranges.3. Discussion
Therapeutic mammaplasty may improve quality of life for
women who would traditionally experience poor cosmetic out-
comes following breast conservation or require a mastectomy as
the primary surgical treatment for their breast cancer, but quality
evidence to support these benefits is currently lacking. Well-
designed prospective data are therefore urgently required to estab-
lish the value of TM and support the on-going provision of the pro-
cedure to women with breast cancer in the UK.
The TeaM study represents the first important step in establish-
ing a definitive evidence-base to support the role of TM as an
essential part of the oncoplastic armamentarium. There are cur-
rently insufficient data to inform the design of a definitive study
of therapeutic mammaplasty in the UK. The TeaM study will gen-
erate high-quality prospective multicentre data regarding the
practice and outcomes of the technique and key information
regarding the timing of contralateral symmetrisation surgery. This
will lead to a well-designed large-scale multicentre cohort study
integrating important patient-reported, cosmetic and long-term
oncological outcomes which will provide much needed evidence
to support practice. The TeaM study will establish current indica-
tions for surgery, establish safety by benchmarking TM against
national quality criteria for oncoplastic breast surgery [21] and
allow predictors for adverse outcomes to be explored. This will
provide important information to help patients and surgeons make
more informed decisions about their surgical options. Furthermore,
the TeaM study will define national standards of care and establish
best practice leading to novel guidelines to support centres offering
the technique. This is an established methodology as data from the
National Mastectomy and Breast Reconstruction Audit [28–31]
was used to develop the current oncoplastic guidelines [21]. This
will improve outcomes for patients through better standardisation
of care.
The use of the trainee collaborative model will allow the study
to be conducted in a time and cost-effective manner. It will furtherconsolidate the infrastructure established by the iBRA study [19]
and facilitate the delivery of the definitive study by establishing
a network of units performing TM who are engaged and interested
in undertaking further work in this area. A national study will pro-
mote increased awareness and understanding of the technique
allowing breast and plastic surgical trainees to learn about the
indications, techniques and outcomes of TM which may also
improve patient care. Finally, this approach will create research
capacity through training future breast and plastic surgeons in
research methodology leading to more and better research that
will ultimately improve outcomes for patients.4. Ethics and dissemination
The proposed study will not affect clinical care and compares
outcomes to published clinical standards. Research ethics approval
is not required and this has been confirmed by the Health Research
Authority (HRA) on-line decision tool (http://www.hra-decision-
tools.org.uk/research/). A study lead will be identified at each par-
ticipating centre. If the unit lead is a trainee, the named
supervising consultant will act as the principal investigator for
the unit for registration purposes. The study lead will be required
to register the audit and obtain local audit approvals for study par-
ticipation prior to commencing patient recruitment. A copy of the
approval will be also forwarded to the TeaM study team. Patient
consent is not required as no patient identifiable data are being
recorded and there is no perceived risk to patients.
The protocol will be disseminated via the collaborative network
including Mammary Fold Breast Trainees’ Group Academic and
Research Collaborative (MFAC), the Reconstructive Surgery Trials
Network (RSTN), the Association of Surgeons in Training (ASiT)
and the National Research Collaborative (NRC) as well as the pro-
fessional associations the Association of Breast Surgery (ABS) and
the British Association of Plastic Reconstructive and Aesthetic Sur-
geons (BAPRAS). The protocol and data collection sheets will be
available on line (www.themammaryfold.com). Individual centres
will have access to their own data. Rates of re-operation and read-
mission following TM will be calculated for each unit and com-
pared with the national average and quality standards defined by
the professional association and NICE. Data will be fed back to par-
ticipating centres at the end of the study. Overall audit results and
results from individual centres will be fed back to ABS and BAPRAS.
Collective data will be analysed and the results of the study pre-
sented at relevant scientific meetings and published in peer-
reviewed journals. The results of the study will be used to deter-
mine national standards and inform patients and surgeons consid-
ering surgery in the future.
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